Axonics (NASDAQ:AXNX) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Axonics (NASDAQ:AXNX) issued its quarterly earnings results on Thursday. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.03, Briefing.com reports. The business had revenue of $114.57 million for the quarter, compared to the consensus estimate of $112.83 million. Axonics had a negative net margin of 0.42% and a negative return on equity of 0.27%. The firm’s quarterly revenue was up 23.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.15) EPS.

Axonics Trading Up 0.1 %

Axonics stock opened at $68.49 on Friday. Axonics has a 1 year low of $48.30 and a 1 year high of $69.68. The company has a market cap of $3.49 billion, a PE ratio of -214.03 and a beta of 0.83. The company’s 50-day moving average is $67.59 and its two-hundred day moving average is $67.73.

Analysts Set New Price Targets

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Axonics in a research report on Monday, May 6th. Eight investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $69.57.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.